Study S000305
A Randomized, Parallel-Arm, Double-Blind Study of Efficacy and Safety of Dulaglutide When Added to SGLT2 Inhibitors in Patients With Type 2 Diabetes Mellitus
Included trial: extracted dataClinicalTrials.gov recordStudy Protocol: GBGE (a) Protocol (PDF)Study Protocol: GBGE (b) Protocol (PDF)Statistical Analysis Plan (PDF)
Registration
Registered primary outcomes
- Change From Baseline in Hemoglobin A1c (HbA1c) at 24 Weeks (Treatment-regimen Estimand) [Baseline, Week 24]
- Change From Baseline in the HbA1c at 24 Weeks (Efficacy Estimand) [Baseline, Week 24]
Linked records (3)
Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.
| Record | Title | Year | Design | Identifiers | Link basis |
|---|---|---|---|---|---|
| R0008191 | Weight-dependent and weight-independent effects of dulaglutide on blood pressure in patients with type 2 diabetes. Ferdinand KC, Cardiovascular diabetology | 2023 | Systematic review | PMID 36894938DOI | cites ClinicalTrials.gov:NCT02597049; registry reference DERIVED:36894938 |
| R0020348 | Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial. Ludvik B, The lancet. Diabetes & endocrinology | 2018 | Randomized trial | PMID 29483060DOI | cites ClinicalTrials.gov:NCT02597049; registry reference DERIVED:29483060 |
| R0021793 | Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial. Frías JP, The lancet. Diabetes & endocrinology | 2016 | Randomized trial | PMID 27651331DOI | cites ClinicalTrials.gov:NCT02597049 |